Skip to content Skip to navigation


The Strategic Advisory Board (SAB) is composed of world-leading experts in stem cell and biomaterials technologies. CCRM shares its SAB with the Ontario Institute for Regenerative Medicine (OIRM).

Co- Chairs


Honourary Member

The role of the Founders Advisory Board (FAB) is to provide guidance, contacts and environment scanning for CCRM's activities, and act in an advisory capacity for CCRM's operations.

  • Mick Bhatia, McMaster Stem Cell and Cancer Research Institute, Hamilton
  • James Ellis, SickKids Research Institute, Toronto
  • Armand Keating, University Health Network, Toronto
  • Gordon Keller, McEwen Centre for Regenerative Medicine and University Health Network, Toronto
  • Andras Nagy, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto
  • Janet Rossant, SickKids Research Institute, Toronto
  • Michael Rudnicki, Ottawa Hospital Research Institute, Ottawa
  • Paul Santerre, Institute of Biomaterials & Biomedical Engineering, University of Toronto, Toronto
  • Molly Shoichet, Institute of Biomaterials & Biomedical Engineering, University of Toronto, Toronto
  • Bill Stanford, Ottawa Hospital Research Institute, Ottawa
  • Peter Zandstra, CCRM, Toronto

The CCRM team continues to actively search for high potential Regenerative Medicine (RM) assets, primarily within its member institutions, as well as globally.

The function of the Commercialization Review Committee (CRC) is to review and recommend technologies and projects for investment by CCRM, the business cases for the RM assets and recommend in-licensing and a commercialization strategy for focused commercial development of technology. The CRC is composed of industry experts, members of the Board of Directors, representatives from the Industry Consortium and staff of Member Technology Transfer Offices. CCRM is pleased to have Devyn Smith, PhD as Chair of the CRC.